Basilea Pharmaceutica AG (BPMUF)
- Previous Close
0.00 - Open
44.00 - Bid --
- Ask --
- Day's Range
44.45 - 44.45 - 52 Week Range
38.60 - 51.26 - Volume
100 - Avg. Volume
1 - Market Cap (intraday)
655.226M - Beta (5Y Monthly) 0.70
- PE Ratio (TTM)
-- - EPS (TTM)
-0.08 - Earnings Date Aug 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.
www.basilea.comRecent News: BPMUF
View MorePerformance Overview: BPMUF
Trailing total returns as of 9/24/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BPMUF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BPMUF
View MoreValuation Measures
Market Cap
655.23M
Enterprise Value
713.38M
Trailing P/E
50.35
Forward P/E
15.43
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.55
Price/Book (mrq)
31.44
Enterprise Value/Revenue
4.07
Enterprise Value/EBITDA
24.28
Financial Highlights
Profitability and Income Statement
Profit Margin
-0.44%
Return on Assets (ttm)
-2.05%
Return on Equity (ttm)
-4.10%
Revenue (ttm)
149.02M
Net Income Avi to Common (ttm)
-652k
Diluted EPS (ttm)
-0.08
Balance Sheet and Cash Flow
Total Cash (mrq)
62.96M
Total Debt/Equity (mrq)
669.89%
Levered Free Cash Flow (ttm)
13.88M
Company Insights: BPMUF
BPMUF does not have Company Insights